EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro activity of aztreonam-avibactam and comparators against Enterobacterales isolated from bloodstream infections: ATLAS/ surveillance, 2021–2022

Gian Maria Rossolini iD, Fupin Hu iD, Nandini Sethuraman, Shweta Kamat, Naglaa Mohamed, Gregory Stone, Katherine K Perez iD

Microbiology Spectrum · 04.08.2026 · 14 (8)

DOI: 10.1128/spectrum.00241-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 04.08.2026. Verfasst von Gian Maria Rossolini und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Medicine, University of Florence, and Microbiology and Virology Unit, Careggi University Hospital, Florence, …. Hauptthemen laut MEDLINE: Aztreonam, Anti-Bacterial Agents, Azabicyclo Compounds, Enterobacteriaceae. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Carbapenem-resistant Enterobacterales (CRE) present a major global health concern due to rapid spread, high mortality, and limited treatment options. Metallo-β-lactamase (MBL)-producing CRE, particularly those harboring New Delhi metallo-β-lactamase (NDM) variants and co-expressing other beta-lactamases, are a significant therapeutic challenge as they exhibit resistance to most β-lactam/β-lactamase inhibitor combinations. This study evaluated the in vitro activity of aztreonam-avibactam (ATM-AVI) and comparators against Enterobacterales bloodstream isolates ( N = 10,376) collected between 2021 and 2022 across Africa and the Middle East, Asia-Pacific, Europe, and Latin America, as part of the Antimicrobial Testing Leadership and Surveillance (ATLAS) Global Surveillance Program. Minimum inhibitory concentrations (MICs) were determined by broth microdilution, with susceptibility interpreted using 2025 European Committee on Antimicrobial Susceptibility Testing (EUCAST) criteria, as appropriate. ATM-AVI demonstrated robust activity, inhibiting 99.8% of Enterobacterales at a concentration of ≤4 mg/L (EUCAST susceptibility breakpoint) and maintaining activity across resistance phenotypes, including 99.6% of multi-drug resistant (MDR), 98.9% of CRE, and 99.9% of extended-spectrum beta-lactamases (ESBL) screen-positive isolates. Among MBL-positive CRE isolates, 97.0% were susceptible to ATM-AVI at the EUCAST breakpoint (≤4 mg/L), compared with 52.7% susceptible to cefiderocol at its EUCAST breakpoint (≤2 mg/L). ATM-AVI remained robust against MBL-positive isolates co-carrying ESBLs (97.8%) and other carbapenemases, like Klebsiella pneumoniae carbapenemase (KPC) (100%) and oxacillinase-48 (OXA-48)/OXA-48-like enzymes (98.2%). Among MBL-positive isolates co-carrying AmpC-type β-lactamases, 78.7% were susceptible to ATM-AVI at the EUCAST breakpoint. ATM-AVI demonstrated potent activity against Enterobacterales , including MDR, CRE, and MBL-positive phenotypes, across regions. Its ability to overcome resistance mediated by multiple β-lactamases highlights clinical potential for managing severe infections like bloodstream infections (BSIs), and the need for global surveillance data to drive clinical decision-making and regional stewardship programs. IMPORTANCE Carbapenem-resistant Enterobacterales (CRE) are a serious global health threat due to their rapid spread and limited treatment options. This study highlights the promising potential of aztreonam-avibactam (ATM-AVI) as a powerful treatment against these resistant bacteria. ATM-AVI was tested on a large number of bacterial samples from various regions worldwide and showed strong effectiveness, even against strains that are resistant to most other treatments. This is particularly important for managing severe infections, such as bloodstream infections, which can be life-threatening. The study underscores the need for ongoing global surveillance to guide treatment decisions and improve health outcomes. Patients suffering from infections caused by resistant bacteria, as well as healthcare providers, could greatly benefit from the findings of this research, as it offers hope for more effective treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AztreonamAnti-Bacterial AgentsAzabicyclo CompoundsEnterobacteriaceaeEnterobacteriaceae Infectionsbeta-Lactamase InhibitorsMicrobial Sensitivity TestsHumansbeta-LactamasesCefiderocolLatin AmericaCarbapenem-Resistant EnterobacteriaceaeDrug Combinations

Stichwörter der Autor:innen

CREEnterobacteralesMBLNDMaztreonam-avibactam

Substanzen

AztreonamAnti-Bacterial AgentsAzabicyclo Compoundsbeta-LactamasesCefiderocolbeta-Lactamase Inhibitorsavibactamaztreonam, avibactam drug combinationDrug Combinations

Autor:innen und Institutionen

  • Department of Experimental and Clinical Medicine, University of Florence, and Microbiology and Virology Unit, Careggi University Hospital, Florence, Italy.
  • Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
  • Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
  • Joint Laboratory of Hospital & Enterprise for Pathogen Diagnosis of Drug-resistant Bacterial Infections and Innovative Drug R&D, Shanghai, China.
  • Department of Microbiology, Central Reference Laboratory, Apollo Hospitals, Chennai, India.
  • PPIPL, Mumbai, India.

ORCID-Profile: Gian Maria Rossolini, Fupin Hu, Katherine K Perez

Zitieren

APA

Rossolini, G. M., Hu, F., Sethuraman, N., Kamat, S., Mohamed, N., Stone, G., & Perez, K. K. (2026). In vitro activity of aztreonam-avibactam and comparators against Enterobacterales isolated from bloodstream infections: ATLAS/ surveillance, 2021–2022. Microbiology Spectrum, 14(8). https://doi.org/10.1128/spectrum.00241-26

Vancouver

Rossolini GM, Hu F, Sethuraman N, Kamat S, Mohamed N, Stone G, et al. In vitro activity of aztreonam-avibactam and comparators against Enterobacterales isolated from bloodstream infections: ATLAS/ surveillance, 2021–2022. Microbiology Spectrum. 2026;14(8). doi:10.1128/spectrum.00241-26

BibTeX
@article{Rossolini2026,
  author = {Rossolini, Gian Maria and Hu, Fupin and Sethuraman, Nandini and Kamat, Shweta and Mohamed, Naglaa and Stone, Gregory and Perez, Katherine K},
  title = {In vitro activity of aztreonam-avibactam and comparators against Enterobacterales isolated from bloodstream infections: ATLAS/ surveillance, 2021–2022},
  journal = {Microbiology Spectrum},
  year = {2026},
  volume = {14},
  number = {8},
  doi = {10.1128/spectrum.00241-26}
}
Kostenlos starten →